Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.
Age
55 - No limit years
Sex
ALL
Healthy Volunteers
No
Sun City, Arizona, United States
Little Rock, Arkansas, United States
Rogers, Arkansas, United States
Costa Mesa, California, United States
Glendale, California, United States
Irvine, California, United States
Lemon Grove, California, United States
Long Beach, California, United States
Oceanside, California, United States
Riverside, California, United States
Start Date
August 29, 2016
Primary Completion Date
January 30, 2019
Completion Date
January 30, 2019
Last Updated
June 29, 2021
177
ACTUAL participants
ITI-007
DRUG
Placebo
DRUG
Lead Sponsor
Intra-Cellular Therapies, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions